Ataxin 10 anticorps

N° du produit ABIN2856106

Cet anticorps Lapin Polyclonal détecte spécifiquement Ataxin 10 dans WB et IHC (p). Il présente une réactivité envers Humain.

Aperçu rapide pour Ataxin 10 anticorps (ABIN2856106)

Antigène: Ataxin 10 (ATXN10)

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Ataxin 10 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-Ataxin 10 anticorps

Réactivité croisée: Humain

Attributs du produit: Rabbit Polyclonal antibody to ATXN10 (ataxin 10)
ATXN10 antibody

Purification: Purified by antigen-affinity chromatography.

Immunogène: Recombinant protein encompassing a sequence within the center region of human ATXN10. The exact sequence is proprietary.

Isotype: IgG

Information d'application

Indications d'application: WB: 1:500-1:3000. IHC-P: 1:100-1:1000. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.

Commentaires:

Positive Control: 293T , A431 , HeLa , HepG2 , U87-MG , SK-N-SH , IMR32 , SK-N-AS

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.78 mg/mL

Buffer: 1XPBS ( pH 7), 1 % BSA, 20 % Glycerol, 0.01 % Thimerosal

Agent conservateur: Thimerosal (Merthiolate)

Précaution d'utilisation: This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.

Détails sur Ataxin 10

Antigène: Ataxin 10 (ATXN10)

Autre désignation: ataxin 10

Sujet: The autosomal dominant cerebellar ataxias (ADCAs) are a clinically and genetically heterogeneous group of disorders characterized by ataxia, dysarthria, dysmetria, and intention tremor. All ADCAs involve some degree of cerebellar dysfunction and a varying degree of signs from other components of the nervous system. A commonly accepted clinical classification (Harding, 1993) divides ADCAs into 3 different groups based on the presence or absence of associated symptoms such as brainstem signs or retinopathy. The presence of pyramidal and extrapyramidal symptoms and ophthalmoplegia makes the diagnosis of ADCA I, the presence of retinopathy points to ADCA II, and the absence of associated signs to ADCA III. Genetic linkage and molecular analyses revealed that ADCAs are genetically heterogeneous even within the various subtypes.[supplied by OMIM]

Poids moléculaire: 53 kDa

ID gène: 25814

UniProt: Q9UBB4